HBW Advisory Services LLC Purchases 141 Shares of Johnson & Johnson (NYSE:JNJ)

HBW Advisory Services LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,534 shares of the company’s stock after buying an additional 141 shares during the quarter. HBW Advisory Services LLC’s holdings in Johnson & Johnson were worth $945,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Biltmore Family Office LLC boosted its holdings in shares of Johnson & Johnson by 13.3% during the second quarter. Biltmore Family Office LLC now owns 16,146 shares of the company’s stock worth $2,360,000 after acquiring an additional 1,894 shares during the period. America First Investment Advisors LLC raised its stake in Johnson & Johnson by 10.9% in the 2nd quarter. America First Investment Advisors LLC now owns 123,996 shares of the company’s stock worth $18,123,000 after purchasing an additional 12,171 shares in the last quarter. Greenwood Gearhart Inc. lifted its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Greenwood Gearhart Inc. now owns 71,781 shares of the company’s stock valued at $10,492,000 after acquiring an additional 1,108 shares during the period. Marco Investment Management LLC grew its holdings in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Marco Investment Management LLC now owns 29,104 shares of the company’s stock worth $4,254,000 after purchasing an additional 181 shares in the last quarter. Finally, HHM Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 16.6% in the second quarter. HHM Wealth Advisors LLC now owns 3,978 shares of the company’s stock worth $581,000 after purchasing an additional 565 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

NYSE JNJ opened at $142.07 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $342.05 billion, a PE ratio of 20.56, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The business’s 50-day moving average price is $149.67 and its two-hundred day moving average price is $155.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter last year, the business earned $2.66 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.49%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Bank of America reiterated a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.